Secondary Logo

Most Popular Articles

Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders

Rey, María Verónica; Molina, Luis; Recinos, Byron; More

Clinical Neuropharmacology. 41(5):177-180, September/October 2018.

Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity

Pérez-Arredondo, Adán; Cázares-Ramírez, Eduardo; Carrillo-Mora, Paul; More

Clinical Neuropharmacology. 39(6):311-319, November/December 2016.

Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients

Kitta, Takeya; Yabe, Ichiro; Kanno, Yukiko; More

Clinical Neuropharmacology. 41(3):98-102, May/June 2018.

Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs

Gony, Mireille; Lapeyre–Mestre, Maryse; Montastruc, Jean-Louis; More

Clinical Neuropharmacology. 26(3):142-145, May-June 2003.

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis

LeWitt, Peter A.; Verhagen Metman, Leo; Rubens, Robert; More

Clinical Neuropharmacology. 41(2):47-55, March/April 2018.

Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

Aragona, Massimiliano; Onesti, Emanuela; Tomassini, Valentina; More

Clinical Neuropharmacology. 32(1):41-47, January-February 2009.

Show: